|
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease.
|
11427204 |
2001 |
|
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Association between PAI-1 polymorphisms and phenotypes related to metabolic syndrome were statistically studied.
|
12856128 |
2003 |
|
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate the influence of polymorphism A36G of the TNF receptor 1 (TNFRSF1A +36A/G) on plasma concentrations of PAI-1 in 163 obese (31 with the metabolic syndrome, MetS) and 150 lean, healthy women.
|
17200772 |
2007 |
|
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.
|
19619703 |
2009 |
|
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The common promoter -675 4G/5G insertion/deletion polymorphism (indel) in the plasminogen activator inhibitor-1 (PAI-1) gene has been associated with quantitative components of the metabolic syndrome.
|
17555513 |
2007 |
|
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to analyze the allele and genotype frequencies of these polymorphisms in PAI-1 gene and its association with metabolic syndrome and its components in a sample of Mexican mestizo children.
|
22459021 |
2012 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Elevated PAI-1 antigen levels have been identified as a potential biomarker for coronary artery disease and metabolic syndrome while being modulated by a number of atherosclerotic risk factors.
|
29494856 |
2018 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Women with MetS had higher values of PAI-1 (36.0 ± 19.1 vs 19.3 ± 14.8 ng/mL, p < .001); in contrast, no differences were observed when compared by hormonal status (20.7 ± 18.10 vs 20.2 ± 17.0 ng/mL, NS).
|
31023101 |
2019 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
In addition, PAI-1 values correlated significantly with metabolic syndrome components and carotid IMT.
|
28822973 |
2018 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Cell adhesion molecules and plasminogen activator inhibitor type-1 (PAI-1) in patients with rheumatoid arthritis: influence of metabolic syndrome.
|
30008151 |
2018 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Strong association between PAI-1 and the metabolic components of the insulin resistance syndrome is found in clinical studies, suggesting that insulin resistance may regulate circulating PAI-1.
|
10665338 |
1999 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1) plays a central role in fibrolysis and has recently been hypothesized to influence components of the insulin resistance syndrome.
|
15297806 |
2004 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Adipose tissue macrophages: a piece of the PAI of metabolic syndrome.
|
20371488 |
2010 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
To compare circulating pigment epithelium derived factor (PEDF) levels in type 2 diabetes patients (T2D) with and without metabolic syndrome (MetS+/-) to healthy controls and assess PEDF association with plasminogen activator inhibitor-1 (PAI-1) and von Willebrand factor (vWF) as markers of endothelial dysfunction.
|
30904010 |
2019 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
A tendency to increase the inflammatory markers IL-6 (p = 0.069) and MCP-1 (p = 0.067) was observed in those patients suffering from MS. An increase in the cardiovascular risk markers PAI-1 (p = 0.007) and triglycerides/HDL cholesterol ratio (p < 0.0001) was also found in the MS group.
|
30924020 |
2019 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
There were significant associations between metabolic syndrome (MetS) and E-selectin and PAI-1.
|
29400123 |
2018 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Positive correlations between PAI-1 and waist circumference and BMI, and negative correlations between BMI and antioxidative defense in the pre-metabolic syndrome patients show that this early stage preceding the metabolic syndrome is also characterized by atherosclerotic complication risks and evident hyperinsulinism and insulin resistance.
|
17848118 |
2007 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Since obesity and metabolic syndrome are now epidemic, and will likely have a major adverse impact on vascular thrombotic events, it may be time to test the clinical effectiveness of PAI-1 inhibition in a patient population at high risk for vascular thrombosis.
|
17896948 |
2007 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
In conclusion, CAM levels are associated with psoriasis diagnosis and MetS may influence E-selectin and PAI-1 concentrations.
|
31758356 |
2020 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
We demonstrated that the increase of sICAM-1, sVCAM-1 and PAI-1, together with decrease of omentin-1 led to a proinflammatory imbalance pointing to the presence of subclinical atherosclerosis, and improving CVD risk stratification in non-smoking patients at early stage MetS beyond traditional scores.
|
31349950 |
2019 |
|
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Increased plasma levels of plasminogen activator inhibitor-1 (PAI-1) have been suggested to be a part of the insulin resistance syndrome, and recent data suggest that adipose tissue participates in the production of PAI-1.
|
11025560 |
2000 |
|
Metabolic Syndrome X
|
0.300 |
Therapeutic
|
disease |
RGD |
Pioglitazone in adult rats reverses immediate postnatal overfeeding-induced metabolic, hormonal, and inflammatory alterations.
|
26084260 |
2015 |
|
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Its predictive ability for MetS and T2DM should not be assessed independently of PAI-1 levels.
|
21800006 |
2011 |
|
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Plasma PAI-1 antigen and activity levels are associated with increased body mass index and with features of the insulin resistance syndrome like obesity and diabetes.
|
28605281 |
2017 |
|
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In 29 children and adolescents with stable renal transplants, we related plasma PAI-1 activity to an indicator of inflammatory status [plasma concentration of C-reactive protein (CRP)] and to elements of the insulin resistance syndrome [body mass index (BMI), fasting insulinemia, HOMA index and plasma triglyceride, HDL-cholesterol, apolipoproteins A-1 and B concentrations].
|
12761670 |
2003 |